Real-world effectiveness and safety of pembrolizumab in mismatch repair-deficient (dMMR) gastrointestinal non-colorectal tumors.

MLA

Martinez Lago, Nieves, et al. “Real-World Effectiveness and Safety of Pembrolizumab in Mismatch Repair-Deficient (DMMR) Gastrointestinal Non-Colorectal Tumors.” Journal of Clinical Oncology, vol. 42, Jan. 2024, p. 733. EBSCOhost, https://doi.org/10.1200/JCO.2024.42.3_suppl.733.

APA

Martinez Lago, N., Gonzalez Villarroel, P., Cousillas Castiñeira, A., Grana Suarez, B., Gallardo Martin, E., Agraso Busto, S., Carral Maseda, A., Fernandez Montes, A., Vazquez, M. F., & Reboredo Lopez, M. (2024). Real-world effectiveness and safety of pembrolizumab in mismatch repair-deficient (dMMR) gastrointestinal non-colorectal tumors. Journal of Clinical Oncology, 42, 733. https://doi.org/10.1200/JCO.2024.42.3_suppl.733

Chicago

Martinez Lago, Nieves, Paula Gonzalez Villarroel, Antia Cousillas Castiñeira, Begona Grana Suarez, Elena Gallardo Martin, Sara Agraso Busto, Alberto Carral Maseda, Ana Fernandez Montes, Maria Francisca Vazquez, and Margarita Reboredo Lopez. 2024. “Real-World Effectiveness and Safety of Pembrolizumab in Mismatch Repair-Deficient (DMMR) Gastrointestinal Non-Colorectal Tumors.” Journal of Clinical Oncology 42 (January): 733. doi:10.1200/JCO.2024.42.3_suppl.733.